骨桥蛋白在肝脏疾病中的作用机制和意义

刘启琳; 王中峰; 许芳; 沙秀娟; 高普均

doi:10.3969/j.issn.1001-5256.2014.04.024

骨桥蛋白在肝脏疾病中的作用机制和意义

DOI: 10.3969/j.issn.1001-5256.2014.04.024

1. 吉林大学白求恩第一医院肝胆胰内科
2. 常州市第三人民医院感染科

详细信息

中图分类号: R575
计量
- 文章访问数: 3009
- HTML全文浏览量: 13
- PDF下载量: 569
- 被引次数: 0
出版历程
- 出版日期: 2014-04-20

Research advances in osteopontin and liver diseases

Department of Hepatobiliary and Pancreatic Medicine, The First Hospital of Jilin University

摘要

摘要:
近20余年来,有关骨桥蛋白(OPN)的生物特性及作用等研究发展迅速。OPN由多种组织细胞合成与分泌。该蛋白结构上与多种基质蛋白相似,功能上具有细胞因子的特点,它在体内参与多种生理和病理活动,包括炎症、损伤修复、骨骼形成和重建,以及癌症和肝脏疾病等。综述了目前有关骨桥蛋白的生物特性研究,及其在肝炎、肝纤维化、肝脏恶性肿瘤中发挥作用等机制。这些资料不仅揭示了相关疾病条件下,OPN在上述疾病发生、发展中所扮演的关键角色,而且指出了通过检测OPN或阻断OPN表达可以保护和治疗肝炎、肝纤维化、肝脏恶性肿瘤这一潜在的临床意义。
- 骨桥蛋白质 /
- 肝炎 /
- 肝硬化 /
- 肝肿瘤 /
- 综述
Abstract:
There has been rapid research progress in the biological characteristics and function of osteopontin (OPN) over the last 20 years.OPN, synthesized and secreted by many tissue cells, has a similar structure as many matrix proteins and possesses the functional characteristics of cytokines.It is involved in the physiological and pathological processes such as inflammation, wound healing, bone formation, and remodeling, as well as development of cancer and liver diseases.Recent studies on the biological characteristics of OPN and its role in hepatitis, liver fibrosis, and liver cancer are reviewed.These studies have shown that abnormal changes in OPN expression occur in many liver diseases and may play an important role in the development and progression of these diseases and that detecting or suppressing OPN expression is of clinical significance for preventing and treating hepatitis, liver fibrosis, and liver cancer.
- osteopontin /
- hepatitis /
- liver cirrhosis /
- liver neoplasms /
- review

HTML全文

参考文献(41)

[1]SENGER DR, WIRTH DF, HYNES RO.Transformed mammalian cells secrete specific proteins and phosphoproteins[J].Cell, 1979, 16 (4) :885-893.

[2]OLDBERG A, FRANZEN A, HEINEGARD D.Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence[J].Proc Natl Acad Sci U S A, 1986, 83 (23) :8819-8823.

[3]MUSSO G, PASCHETTA E, GAMBINO R, et al.Interactions among bone, liver, and adipose tissue predisposing to diabesity and fatty liver[J].Trends Mol Med, 2013, 19 (9) :522-535.

[4]KAWASHIMA R, MOCHIDA S, MATSUI A, et al.Expression of osteopontin in Kupffer cells and hepatic macrophages and Stellate cells in rat liver after carbon tetrachloride intoxication:a possible factor for macrophage migration into hepatic necrotic areas[J].Biochem Biophys Res Commun, 1999, 256 (3) :527-531.

[5]RAMAIAH SK, RITTLING S.Pathophysiological role of osteopontin in hepatic inflammation, toxicity, and cancer[J].Toxicol Sci, 2008, 103 (1) :4-13.

[6]GIMBA ER, TILLI TM.Human osteopontin splicing isoforms:known roles, potential clinical applications and activated signaling pathways[J].Cancer Lett, 2013, 331 (1) :11-17.

[7]YOKOSAKI Y, TANAKA K, HIGASHIKAWA F, et al.Distinct structural requirements for binding of the integrins alphavbeta6, alphavbeta3, alphavbeta5, alpha5beta1 and alpha9beta1 to osteopontin[J].Matrix Biol, 2005, 24 (6) :418-427.

[8]SODEK J, GANSS B, McKEE MD.Osteopontin[J].Crit Rev Oral Biol Med, 2000, 11 (3) :279-303.

[9]CHA JH, AHN YH, LIM SW, et al.Decreased osteopontin expression in the rat kidney on a sodium deficient diet[J].Yonsei Med J, 2000, 41 (1) :128-135.

[10]ISODA K.Osteopontin Transgenic Mice Fed a High-Cholesterol Diet Develop Early Fatty-Streak Lesions[J].Circulation, 2003, 107 (5) :679-681.

[11]APTE UM, BANERJEE A, McREE R, et al.Role of osteopontin in hepatic neutrophil infiltration during alcoholic steatohepatitis[J].Toxicol Appl Pharmacol, 2005, 207 (1) :25-38.

[12]MORALES-IBANEZ O, DOMINGUEZ M, KI SH, et al.Human and experimental evidence supporting a role for osteopontin in alcoholic hepatitis[J].Hepatology, 2013, 58 (5) :1742-1756.

[13]YILMAZ Y, OZTURK O, ALAHDAB YO, et al.Serum osteopontin levels as a predictor of portal inflammation in patients with nonalcoholic fatty liver disease[J].Dig Liver Dis, 2013, 45 (1) :58-62.

[14]DIAO H, LIU X, WU Z, et al.Osteopontin regulates interleukin-17 production in hepatitis[J].Cytokine, 2012, 60 (1) :129-137.

[15]FAN K, ZHANG B, YANG H, et al.A humanized anti-osteopontin antibody protects from Concanavalin A induced-liver injury in mice[J].Eur J Pharmacol, 2011, 657 (1-3) :144-151.

[16]KIEFER FW, NESCHEN S, PFAU B, et al.Osteopontin deficiency protects against obesity-induced hepatic steatosis and attenuates glucose production in mice[J].Diabetologia, 2011, 54 (8) :2132-2142.

[17]BASSYOUNI IH, BASSYOUNI RH, IBRAHIM NH, et al.Elevated serum osteopontin levels in chronic hepatitis C virus infection:association with autoimmune rheumatologic manifestations[J].J Clin Immunol, 2012, 32 (6) :1262-1269.

[18]SHAKER O, EL-SHEHABY A, FAYEZ S, et al.Osteopontin gene polymorphisms as predictors for the efficacy of interferon therapy in chronic hepatitis C Egyptian patients with genotype 4[J].Cell Biochem Funct, 2013, 31 (7) :620-625.

[19]ZHAO L, LI T, WANG Y, et al.Elevated plasma osteopontin level is predictive of cirrhosis in patients with hepatitis B infection[J].Int J Clin Pract, 2008, 62 (7) :1056-1062.

[20]HUANG W, ZHU G, HUANG M, et al.Plasma osteopontin concentration correlates with the severity of hepatic fibrosis and inflammation in HCV-infected subjects[J].Clin Chim Acta, 2010, 411 (9-10) :675-678.

[21]SYN WK, AGBOOLA KM, SWIDERSKA M, et al.NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease[J].Gut, 2012, 61 (9) :1323-1329.

[22]TOKAIRIN T, NISHIKAWA Y, WATANABE H, et al.Osteopontin expression in the liver with severe perisinusoidal fibrosis:autopsy case of Down syndrome with transient myeloproliferative disorder[J].Pathol Int, 2008, 58 (1) :64-68.

[23]XIAO X, GANG Y, GU Y, et al.Osteopontin contributes to TGF-beta1 mediated hepatic stellate cell activation[J].Dig Dis Sci, 2012, 57 (11) :2883-2891.

[24]URTASUN R, LOPATEGI A, GEORGE J, et al.Osteopontin, an oxidant stress sensitive cytokine, up-regulates collagen-I via integrin alpha (V) beta (3) engagement and PI3K/pAkt/NFkappaB signaling[J].Hepatology, 2012, 55 (2) :594-608.

[25]PRITCHETT J, HARVEY E, ATHWAL V, et al.Osteopontin is a novel downstream target of SOX9 with diagnostic implications for progression of liver fibrosis in humans[J].Hepatology, 2012, 56 (3) :1108-1116.

[26]CHEN BL, ZHANG GY, YUAN WJ, et al.Osteopontin expression is associated with hepatopathologic changes in Schistosoma japonicum infected mice[J].World J Gastroenterol, 2011, 17 (46) :5075-5082.

[27]NAGOSHI S.Osteopontin:Versatile modulator of liver diseases[J].Hepatol Res, 2014, 44 (1) :22-30.

[28]LIU W, XU G, MA J, et al.Osteopontin as a key mediator for vasculogenic mimicry in hepatocellular carcinoma[J].Tohoku J Exp Med, 2011, 224 (1) :29-39.

[29]ZHANG R, PAN X, HUANG Z, et al.osteopontin enhances the expression and activity of MMP-2 via the SDF-1/CXCR4 axis in hepatocellular carcinoma cell lines[J].PLoS One, 2011, 6 (8) :e23831.

[30]PHILLIPS RJ, HELBIG KJ, van der HOEK KH, et al.Osteopontin increases hepatocellular carcinoma cell growth in a CD44 dependant manner[J].World J Gastroenterol, 2012, 18 (26) :3389-3399.

[31]CHEN RX, XIA YH, XUE TC, et al.Transcription factor c-Myb promotes the invasion of hepatocellular carcinoma cells via increasing osteopontin expression[J].J Exp Clin Cancer Res, 2010, 29:172.

[32]WU Y, JIANG W, WANG Y, et al.Breast cancer metastasis suppressor 1 regulates hepatocellular carcinoma cell apoptosis via suppressing osteopontin expression[J].PLoS One, 2012, 7 (8) :e42976.

[33]XUE YH, ZHANG XF, DONG QZ, et al.Thrombin is a therapeutic target for metastatic osteopontin-positive hepatocellular carcinoma[J].Hepatology, 2010, 52 (6) :2012-2022.

[34]XIE H, SONG J, DU R, et al.Prognostic significance of osteopontin in hepatitis B virus-related hepatocellular carcinoma[J].Dig Liver Dis, 2007, 39 (2) :167-172.

[35]ZHOU C, ZHOU HJ, ZHANG XF, et al.Postoperative serum osteopontin level is a novel monitor for treatment response and tumor recurrence after resection of hepatitis B-related hepatocellular carcinoma[J].Ann Surg Oncol, 2013, 20 (3) :929-937.

[36]EL-DIN BESSA SS, ELWAN NM, SULIMAN GA, et al.Clinical significance of plasma osteopontin level in Egyptian patients with hepatitis C virus-related hepatocellular carcinoma[J].Arch Med Res, 2010, 41 (7) :541-547.

[37]KIM SH, CHUNG YH, YANG SH, et al.Prognostic value of serum osteopontin in hepatocellular carcinoma patients treated with transarterial chemoembolization[J].Korean J Hepatol, 2009, 15 (3) :320-330.

[38]SULPICE L, RAYAR M, DESILLE M, et al.Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma[J].Hepatology, 2013, 58 (6) :1992-2000.

[39]HUANG J, PAN C, HU H, et al.Osteopontin-enhanced hepatic metastasis of colorectal cancer cells[J].PLoS One, 2012, 7 (10) :e47901.

[40]SUN L, PAN J, PENG L, et al.Combination of haptoglobin and osteopontin could predict colorectal cancer hepatic metastasis[J].Ann Surg Oncol, 2012, 19 (7) :2411-2419.

[41]DONG QZ, ZHANG XF, ZHAO Y, et al.Osteopontin promoter polymorphisms at locus-443 significantly affect the metastasis and prognosis of human hepatocellular carcinoma[J].Hepatology, 2013, 57 (3) :1024-1034.

施引文献

资源附件(0)

访问统计